These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 3682501)

  • 1. [Effect of immunotherapy on bladder cancer].
    Watanabe K; Suzuki T; Takahashi N; Kawaguchi T; Kudo T; Kogawa T; Funyu T
    Nihon Hinyokika Gakkai Zasshi; 1987 Jun; 78(6):1092-102. PubMed ID: 3682501
    [No Abstract]   [Full Text] [Related]  

  • 2. [Intravesical bacillus Calmette-Guerin (BCG) in the treatment of superficial bladder tumors: effect of intravesical BCG on papillary tumors].
    Hagiwara M; Asano T; Iigaya T; Tsukamoto T; Nishida K
    Nihon Hinyokika Gakkai Zasshi; 1986 Oct; 77(10):1623-30. PubMed ID: 3820900
    [No Abstract]   [Full Text] [Related]  

  • 3. [Coadjuvant action of chemotherapy and immunotherapy in the carcinoma of the bladder].
    Rodrigues-Netto Júnior N; Napoli F; Lemos GC
    Rev Paul Med; 1979; 94(3-4):51-3. PubMed ID: 121486
    [No Abstract]   [Full Text] [Related]  

  • 4. T1G3: What to do?
    Mandressi A
    Arch Ital Urol Androl; 1996 Feb; 68(1):5-7. PubMed ID: 8664922
    [No Abstract]   [Full Text] [Related]  

  • 5. BCG in management of transitional cell carcinoma invasive to prostate.
    Siami P; Chinn S; Clayton M; Ray V; Rubenstein M; Guinan P
    Urology; 1989 Dec; 34(6):381-2. PubMed ID: 2595884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new staging system for transitional cell carcinoma involvement of the prostate and reconfirmation studies of intravesical therapy for superficial bladder cancer.
    Hudson MR
    J Urol; 1996 Sep; 156(3):972-4. PubMed ID: 8709376
    [No Abstract]   [Full Text] [Related]  

  • 7. Adjuvant immunotherapy in superficial bladder cancer.
    Morales A
    Natl Cancer Inst Monogr; 1978 Dec; (49):315-9. PubMed ID: 748787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Adjuvant local BCG-immunotherapy in patients with urothel cancer of the bladder (author's transl)].
    Flamm J; Grof F
    Wien Med Wochenschr; 1981 Oct; 131(20):501-6. PubMed ID: 7314632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The management of stage T1 grade 3 transitional cell carcinoma of the bladder.
    Evans CP; Busby JE
    BJU Int; 2003 Sep; 92(4):345-8. PubMed ID: 12930415
    [No Abstract]   [Full Text] [Related]  

  • 10. Contemporary management of stage T1 transitional cell carcinoma of the bladder.
    Sataa S; Yassine N; Ghassen HH; Imed BS; Mohamed C; Maher C; Ali H
    Tunis Med; 2005 Dec; 83 Suppl 12():87-9. PubMed ID: 16430077
    [No Abstract]   [Full Text] [Related]  

  • 11. [Preservation of the bladder in transitional cell tumors infiltrating the lamina propria].
    Benoît G; Alexandre L; Bensadoun H; Vieillefond A; Martin PR; Martin A; Jardin A
    Presse Med; 1991 Sep; 20(30):1425-8. PubMed ID: 1835025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Our experience in the treatment of superficial cancer of the bladder with BCG].
    Martínez E; Díaz I; Salvador J; Viladoms JM; Zungri E; Solé-Balcells FJ
    Arch Esp Urol; 1989 May; 42(4):325-7. PubMed ID: 2782959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T2a transitional cell carcinoma of the bladder: long-term experience with intravesical immunoprophylaxis with bacillus Calmette-Guerin.
    Volkmer BG; Gschwend JE; Maier SH; Seidl-Schlick EM; Bach D; Romics I
    J Urol; 2003 Mar; 169(3):931-4; discussion 934-5. PubMed ID: 12576815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The optimal management of T1G3 bladder cancer.
    Emiliozzi P; Pansadoro A; Pansadoro V
    BJU Int; 2008 Nov; 102(9 Pt B):1265-73. PubMed ID: 19035891
    [No Abstract]   [Full Text] [Related]  

  • 15. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update.
    Hall MC; Chang SS; Dalbagni G; Pruthi RS; Seigne JD; Skinner EC; Wolf JS; Schellhammer PF
    J Urol; 2007 Dec; 178(6):2314-30. PubMed ID: 17993339
    [No Abstract]   [Full Text] [Related]  

  • 16. Primary neuroendocrine carcinoma of the urethra.
    Parekh DJ; Jung C; Roberts R; Shappell S; Smith JA
    Urology; 2002 Dec; 60(6):1111. PubMed ID: 12475683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of high-risk, non-muscle-invasive bladder cancer.
    Lerner SP
    Nat Clin Pract Urol; 2006 Aug; 3(8):398-9. PubMed ID: 16902498
    [No Abstract]   [Full Text] [Related]  

  • 18. [Pitfalls in intravesical immunotherapy of superficial carcinoma of the gallbladder with BCG vaccine].
    Pacík D; Vít V; Turjanica M
    Rozhl Chir; 1997 Jan; 76(1):3-5. PubMed ID: 9182342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment and follow-up of superficial bladder cancer].
    Raitanen M
    Duodecim; 2002; 118(9):903-9. PubMed ID: 12238168
    [No Abstract]   [Full Text] [Related]  

  • 20. Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer.
    Lamm DL
    Nihon Hinyokika Gakkai Zasshi; 1995 Jan; 86(1):9-10. PubMed ID: 7897925
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.